Journal
ENDOCRINE PRACTICE
Volume 23, Issue 2, Pages 207-238Publisher
ELSEVIER INC
DOI: 10.4158/EP161682.CS
Keywords
-
Categories
Funding
- AstraZeneca
- Janssen Pharmaceuticals, Inc.
- Lexicon Pharmaceuticals, Inc.
- Merck Co.
- Novo Nordisk
- Sanofi
- Amgen
- Boehringer Ingelheim
- Takeda
- Janssen
- Eli Lilly
- Eisai
- Asahi
- Abbott
- Endo Barrier
- Bayer
- Gilead
- Merck
- Weight Watchers
- Lexicon
- Pfizer
- Elcelyx
- Medtronic
- Regeneron
- BI
- Esperion
- Grifols
- Hamni
- GlaxoSmithKline
- Novartis
- Dexcom
- Bristol Myers Squibb
- Ionis
- Orexigen
Ask authors/readers for more resources
This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available